Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

The CF Foundation urges all states to include newborn screening for cystic fibrosis in test panels

15.10.2004


Similar recommendations issued from the CDC based on benefits of early diagnosis



The Cystic Fibrosis Foundation today issued a recommendation for the implementation of routine cystic fibrosis (CF) screening in all newborns. In addition, the Centers for Disease Control and Prevention (CDC) issued a recommendation in its October 15 Morbidity and Mortality Weekly Report (MMWR) Reports and Recommendations that all states should consider routine screening for CF in all newborns. CF Foundation-supported research and peer-reviewed evidence conducted and gathered over the past two decades have demonstrated the benefits of newborn screening for CF. People with CF who are diagnosed at birth gain more weight and have better nutrition than those who are diagnosed later in life. Better nutrition and weight gain in children with CF has been linked to a slower decline in respiratory function, the primary cause of death in CF.

Advances in CF treatment and care, have had a significant impact on the length and quality of life for people with CF. Research on newborn screening for CF has shown further clinical benefit when therapeutic interventions were administered near the beginning of life. Early diagnosis allows a special high-calorie, high-fat diet, along with pancreatic enzyme and fat soluble vitamin supplementation to begin immediately, if needed, before digestive complications occur. Better nutrition has been linked to improved height and weight measurements, better pulmonary status, and cognitive benefits.


"It is imperative that states add newborn screening for CF to their test panels to give people with this disease the best odds at living longer, healthier lives," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "The CF Foundation is prepared to be a resource of knowledge and expertise for states as they consider this important recommendation and begin implementing newborn screening for CF."

Although new therapies and specialized care have extended the lives of people with CF, the average age of diagnosis--approximately 3 years--has remained the same. Traditionally, children with CF are not diagnosed unless CF has been present in a family’s history or until symptoms appear. In many cases, delayed diagnosis has resulted in irreversible nutritional and pulmonary morbidities. By making a CF diagnosis sooner, therapeutic interventions can minimize and postpone the development of symptoms, which can slow the progression of the disease.

Implementation of CF Newborn Screening

Participants in a recent workshop hosted by the CF Foundation discussed how to implement routine newborn screening for CF, as well as how the CF Foundation and its nationwide network of accredited care centers can ensure the best care for newborns before classic CF symptoms develop. The CF Foundation will work closely with state governments to urge the inclusion of CF on newborn screening test panels and will provide guidance on optimum test procedures and the elements of a comprehensive program. The CF Foundation also will encourage states to refer parents of newly diagnosed infants to its accredited care centers. These centers provide state-of-the-art specialty care and the opportunity for infants to benefit from medical advances. In addition, these centers will continue to track demographic, diagnostic, and treatment data via the CF Foundation’s national Patient Registry to further improve their care. Newborn screening for CF also will enable new treatment options for infants to be evaluated and developed.

"After reviewing and carefully considering the scientific evidence, the benefits of newborn screening for CF are now clear. We now must turn our attention to ensuring that parents of newborns diagnosed with CF are given the educational resources they need to care for their children and that they receive appropriate treatment from CF experts," said Preston W. Campbell, III, M.D., executive vice president of medical affairs of the CF Foundation. "I am eager to witness the improvements that CF newborn screening will inevitably bring to people with CF and am proud of the CF Foundation’s leadership role in this initiative."

The newborn screening tests for CF are not diagnostic tools. If the initial screen is positive, then further tests are done to rule out or confirm a CF diagnosis. Only a fraction of newborns with a positive initial screen ultimately will be diagnosed with CF. Currently, seven states conduct CF newborn screening in all newborns; three states screen for CF in some hospitals or populations; while two more states are now implementing CF screening programs. From 1990 to 1999, 1.46 million babies were screened for CF and 372 were ultimately diagnosed with CF. CF is one of the most common disorders identified in the newborn screening programs that include it in their testing.

Allison Tobin | EurekAlert!
Further information:
http://www.cff.org

More articles from Health and Medicine:

nachricht New antibody analysis accelerates rational vaccine design
09.08.2018 | Scripps Research Institute

nachricht Distrust of power influences choice of medical procedures
01.08.2018 | Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

Im Focus: World record: Fastest 3-D tomographic images at BESSY II

The quality of materials often depends on the manufacturing process. In casting and welding, for example, the rate at which melts solidify and the resulting microstructure of the alloy is important. With metallic foams as well, it depends on exactly how the foaming process takes place. To understand these processes fully requires fast sensing capability. The fastest 3D tomographic images to date have now been achieved at the BESSY II X-ray source operated by the Helmholtz-Zentrum Berlin.

Dr. Francisco Garcia-Moreno and his team have designed a turntable that rotates ultra-stably about its axis at a constant rotational speed. This really depends...

Im Focus: A molecular switch may serve as new target point for cancer and diabetes therapies

If certain signaling cascades are misregulated, diseases like cancer, obesity and diabetes may occur. A mechanism recently discovered by scientists at the Leibniz- Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin and at the University of Geneva has a crucial influence on such signaling cascades and may be an important key for the future development of therapies against these diseases. The results of the study have just been published in the prestigious scientific journal 'Molecular Cell'.

Cell growth and cell differentiation as well as the release and efficacy of hormones such as insulin depend on the presence of lipids. Lipids are small...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

NRL's sun imaging telescopes fly on NASA Parker Solar Probe

13.08.2018 | Physics and Astronomy

UT-ORNL team makes first particle accelerator beam measurement in six dimensions

13.08.2018 | Physics and Astronomy

ASU astrophysicist helps discover that ultrahot planets have starlike atmospheres

13.08.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>